As the glioma immune microenvironment exhibits abundant extracellular TGF-beta, ongoing Phase I trials of YM101 and related bispecific antibodies may unlock exceptional responses beyond anti-PD-L1 monotherapy. The gene discussed is CD274; the disease is glioma.